# Verification Summary

**Plan reviewed:** `thoughts/shared/plans/2026-08-27-align-prp-nsaid-protocol.md`
**Overall readiness:** Ready

The plan matches the current repository and is implementable without schema changes. Two minor issues found during verification were corrected in the plan before approval: it now makes a single committed choice for the canonical field name, and it uses the repository's actual verification commands (`npm run lint` and `npx tsc --noEmit`) because no `typecheck` package script exists.

## Findings

### Minor — canonical field decision was initially ambiguous

**Location:** Phase 1, `src/lib/clinical/prp-protocol.ts`

The draft offered either `avoidanceWindowWeeks` or the existing `protectiveWindowWeeks`, leaving an implementation choice unresolved. The plan now explicitly selects `avoidanceWindowWeeks: 2` and removes all three current duration fields.

**Status:** Resolved in plan.

### Minor — type-check command was not concrete

**Location:** Phase 1 and Phase 3 automated verification

`package.json` contains `lint` and `test` scripts but no dedicated type-check script. The plan now specifies `npx tsc --noEmit` and `npm run lint` directly.

**Status:** Resolved in plan.

### Minor — shared generator also accepts BOTOX records

**Location:** Phase 2, `src/lib/claude/generate-procedure-note.ts`

The base system prompt is PRP-specific, but BOTOX generation appends `BOTOX_PROMPT_OVERRIDE`, which explicitly supersedes PRP wording. The planned PRP NSAID guard is compatible with the current architecture, provided the override remains unchanged. The plan now records this constraint explicitly.

**Status:** Resolved in plan.

## Missing Work

No required work is missing for the scoped duration and aftercare consistency fix.

Structured NSAID clearance remains intentionally out of scope. The repository has no last-use or clearance field, so this plan corrects what the application says but does not create source-backed proof of compliance. That limitation is clearly documented in the plan and should be handled as a separate clinical-intake feature if requested.

## Risks

- The change makes two weeks the minimum documented hold, which is a clinical-policy decision. The plan appropriately anchors this to the user's stated requirement.
- Existing finalized records will retain old wording; the plan correctly avoids mutating signed clinical documents.
- The LLM can paraphrase prompt content, so consumer-level positive and negative prompt tests are important. The plan includes both.
- Aspirin appears both as an antiplatelet and in general NSAID examples. The plan preserves current medication-specific behavior rather than expanding scope.

## Suggested Changes

All required revisions have already been incorporated into the implementation plan. During implementation, keep negative phrase assertions scoped to the PRP post-care section so unrelated source text or the BOTOX override does not create brittle failures.

## Final Recommendation

Approve implementation. The plan is technically consistent with the current codebase, uses existing helper and test patterns, defines concrete verification, and has a low-complexity rollback because it requires no migration or data rewrite.
